Rethinking cancer clinical trials for COVID-19 and beyond
- 29 May 2020
- journal article
- editorial
- Published by Springer Nature in Nature Cancer
- Vol. 1 (6) , 568-572
Abstract
The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential to ensure the resilience of clinical cancer research and optimize patient-centered care.Keywords
This publication has 14 references indexed in Scilit:
- Adapting to a Pandemic — Conducting Oncology Trials during the SARS-CoV-2 PandemicClinical Cancer Research, 2020
- Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemicThe Lancet Oncology, 2020
- Detection of ctDNA from Dried Blood Spots after DNA Size SelectionClinical Chemistry, 2020
- Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancerBreast Cancer Research and Treatment, 2020
- The Future of Wearable Technologies and Remote Monitoring in Health CareAmerican Society of Clinical Oncology Educational Book, 2019
- A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndromeInternational Journal of Cardiology, 2018
- Perspectives on Electronic Informed Consent From Patients Underrepresented in Research in the United States: A Focus Group StudyJournal of Empirical Research on Human Research Ethics, 2018
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementJournal of Clinical Oncology, 2017
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- Electronic informed consenting: A boon to modernize consenting processPerspectives in Clinical Research, 2015